Antisolvent Crystallization Using Ionic Liquids As Solvent and Antisolvent for Polymorphic Design of Active Pharmaceutical Ingredient

被引:46
|
作者
An, Ji-Hun [1 ]
Kim, Woo-Sik [1 ]
机构
[1] Kyung Hee Univ, ILRI, Dept Chem Engn, Kyonggi Do 449701, South Korea
关键词
PLUS WATER MIXTURES; CRYSTAL NUCLEATION; DRUG PHASE; CHEMISTRY;
D O I
10.1021/cg300730w
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The applicability of ionic liquids to the polymorphic design of the active pharmaceutical ingredient adefovir dipivoxil (AD) was investigated in the case of antisolvent crystallization. When using 1-allyl-3-ethylimidazolium tetrafluoroborate (AEImBF(4)) as the solvent and 1-butyl-2,3dimethylimidazolium tetrafluoroborate (BDMImBF(4)) as the antisolvent (AEImBF(4)/BDMImBF(4)), a new form (NF) of All crystal was obtained at a crystallization temperature below 50 degrees C and initial solute concentration of 25.6 mg/mL. However, when using 1-allyl-3-ethylimidazolium tetrafluoroborate/1,3-diallylimidazolium tetrafluoroborate (AEImBF(4)/AAImBF(4)) and 1-allyl-3-ethylimidazolium tetrafluoroborate/1-ethyl-3-methylimidazolium ethylsulfate (AEImBF(4)/EMImEtSO(4)), the conventional form-I polymorph was directly crystallized. No crystallization occurred in the ionic solutions of 1-allyl-3-ethylimidazolium tetrafluoroborate/1-allyl-3-ethylimidazolium bromide (AEImBF(4)/AEImBr) and 1-allyl-3-ethylimidazolium tetrafluoroborate/1,3-diallylimidazolium bromide (AEImBF(4)/AAImBr). According to a spectroscopic analysis, the polymorphs were predominantly determined by the preorientation of the solute molecules in the ionic liquid solution (AEImBF(4)/BDMImBF(4)), and this preorientation varied according to the crystallization temperature. Thus, the pure form-X polymorph was nucleated at a crystallization temperature above 80 degrees C. Plus, the polymorphic nucleation depending on the crystallization temperature was also combined with the crystallization concentration. Thus, the minimum crystallization temperature for the nucleation of the pure form-X polymorph was reduced to 40 degrees C when decreasing the crystallization concentration to 15 mg/mL. The relationship between the polymorphic nucleation and the crystallization conditions was effectively predicted by a polymorphic supersaturation level diagram (S-NF-Sform-X diagram), where the formation of the metastable polymorph (NF crystals) was favored at a high supersaturation level (S-NF > 2.1), while the stable polymorph (form-X crystals) was preferentially nucleated at a low supersaturation level (S-NF < 1.6). Differental scanning calorimetry thermal analysis confirmed that the NF polymorph was the metastable phase and the form-X polymorph was the stable phase, and there was a monotropic relationship between the two polymorphs.
引用
收藏
页码:31 / 39
页数:9
相关论文
共 50 条
  • [1] Computer Aided Design of Solvent Blends for Hybrid Cooling and Antisolvent Crystallization of Active Pharmaceutical Ingredients
    Watson, Oliver L.
    Jonuzaj, Suela
    McGinty, John
    Sefcik, Jan
    Galindo, Amparo
    Jackson, George
    Adjiman, Claire S.
    [J]. Organic Process Research and Development, 2021, 25 (05): : 1123 - 1142
  • [2] Computer Aided Design of Solvent Blends for Hybrid Cooling and Antisolvent Crystallization of Active Pharmaceutical Ingredients
    Watson, Oliver L.
    Jonuzaj, Suela
    McGinty, John
    Sefcik, Jan
    Galindo, Amparo
    Jackson, George
    Adjiman, Claire S.
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2021, 25 (05) : 1123 - 1142
  • [3] Enhanced Water Solubility and Oral Bioavailability of Paclitaxel Crystal Powders through an Innovative Antisolvent Precipitation Process: Antisolvent Crystallization Using Ionic Liquids as Solvent
    Yang, Qilei
    Zu, Chang
    Li, Wengang
    Wu, Weiwei
    Ge, Yunlong
    Wang, Lingling
    Wang, Li
    Li, Yong
    Zhao, Xiuhua
    [J]. PHARMACEUTICS, 2020, 12 (11) : 1 - 16
  • [4] Progress in antisolvent crystallization in pharmaceutical field
    Huang, Yan
    Sun, Hailong
    Meng, Zichao
    Tang, Zhongli
    Wang, Jingtao
    [J]. Huagong Jinzhan/Chemical Industry and Engineering Progress, 2019, 38 (05): : 2380 - 2388
  • [5] Antisolvent Membrane Crystallization of Pharmaceutical Compounds
    Di Profio, Gianluca
    Stabile, Carmen
    Caridi, Antonella
    Curcio, Efrem
    Drioli, Enrico
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (12) : 4902 - 4913
  • [6] Direct design of pharmaceutical antisolvent crystallization through concentration control
    Zhou, GX
    Fujiwara, M
    Woo, XY
    Rusli, E
    Tung, HH
    Starbuck, C
    Davidson, O
    Ge, ZH
    Braatz, RD
    [J]. CRYSTAL GROWTH & DESIGN, 2006, 6 (04) : 892 - 898
  • [7] Antisolvent crystallization kinetics of different substances in solvent-antisolvent systems
    Sangwal, Keshra
    Polak, Wieslaw Z.
    [J]. JOURNAL OF CRYSTAL GROWTH, 2024, 628
  • [8] Microparticle Production of Active Pharmaceutical Ingredient Using Supercritical Antisolvent Process: A Case Study of Allopurinol
    Khudaida, Salal Hasan
    Wang, Wei-Kai
    Wu, Wei-Yi
    Su, Chie-Shaan
    [J]. CRYSTALS, 2022, 12 (07)
  • [9] Tailoring the crystal size distribution of an active pharmaceutical ingredient by continuous antisolvent crystallization in a planar oscillatory flow crystallizer
    Cruz, Patricia
    Alvarez, Carlos
    Rocha, Fernando
    Ferreira, Antonio
    [J]. CHEMICAL ENGINEERING RESEARCH & DESIGN, 2021, 175 : 115 - 123
  • [10] Solvent-Antisolvent Competitive Interactions Mediate Imidacloprid Polymorphs in Antisolvent Crystallization
    Xue, Su
    Xu, Jipeng
    Han, You
    Zhang, Jinli
    Li, Wei
    [J]. CRYSTAL GROWTH & DESIGN, 2021, 21 (08) : 4318 - 4328